Skip to main content
Bioceltix S.A. logo

Bioceltix S.A. — Investor Relations & Filings

Ticker · BCX ISIN · PLBCLTX00019 LEI · 259400QZD5JYK8SLZU51 WAR Manufacturing
Open in API
Filings indexed 270 across all filing types
Latest filing 2023-05-08 Regulatory Filings
Country PL Poland
Listing WAR BCX

About Bioceltix S.A.

https://bioceltix.com/en/

Bioceltix S.A. is a biopharmaceutical company that develops stem cell-based medicinal products for veterinary use. The company focuses on creating therapies that utilize Mesenchymal Stem Cells (MSCs) as the active pharmaceutical ingredient. Its product pipeline is aimed at treating immunological and inflammatory conditions in companion animals, including dogs, cats, and horses. A key area of development includes treatments for conditions such as atopic dermatitis in dogs and degenerative joint disease.

Recent filings

Filing Released Lang Actions
Rozpoczęcie fazy badawczej w badaniu klinicznym weterynaryjnym dotyczącym produktu BCX-EM - Content (PL)
Regulatory Filings Classification · 1% confidence The document text is a formal announcement from the Management Board ("Zarząd") of Bioceltix S.A. regarding the commencement of the research phase in a veterinary clinical trial for product BCX-EM. It details the purpose of the trial (confirming efficacy for treating osteoarthritis in horses), the methodology (comparing BCX-EM vs. placebo), and states that the information is considered material because it marks an important step toward potential commercialization. This content relates to the development pipeline and significant operational milestones, which is often disclosed via regulatory announcements. Since there is no specific category for 'Clinical Trial Commencement,' and it is not a standard financial report (10-K, IR, ER), nor a management change (MANG) or director dealing (DIRS), the most appropriate general category for significant, non-standard regulatory updates is 'Regulatory Filings' (RNS). The document length is short (1280 chars), but it is the report itself, not an announcement *about* a report, so RPA is not applicable.
2023-05-08 Polish
Podpisy zaktualizowanego Sprawozdania niezależnego biegłego rewidenta z badania rocznego sprawozdania finansowego Spółki za 2022 rok
Audit Report / Information Classification · 1% confidence The document text consists almost entirely of XML structures related to digital signatures (Signature, SignedInfo, KeyInfo, Object, QualifyingProperties, SignedProperties, etc.). The presence of elements like 'DigestValue', 'X509Certificate', and 'SigningTime' strongly indicates a digitally signed document, likely an XBRL filing or a regulatory document that requires cryptographic verification. Crucially, the content references a file named 'BIOCELTIX_BSF_2022_Sprawozdanie_z_badania_JZP_PSRv2.xhtml'. The Polish phrase 'Sprawozdanie z badania' translates to 'Audit Report' or 'Report on the examination'. Given the content is the signature block of a document whose underlying file is explicitly named as an 'Audit Report' ('Sprawozdanie z badania'), the most appropriate classification is Audit Report / Information (AR). It is not an RPA because it is the signature block itself, not a short announcement pointing to the report. It is not a 10-K because the content points specifically to an audit report, not the full annual report. FY 2022
2023-05-08 Polish
Zaktualizowane Sprawozdanie niezależnego biegłego rewidenta z badania rocznego sprawozdania finansowego Spółki za 2022 rok
Audit Report / Information Classification · 1% confidence The document text is explicitly titled "Sprawozdanie niezależnego biegłego rewidenta z badania rocznego sprawozdania finansowego" (Independent Auditor's Report on the Audit of the Annual Financial Statements) for the year ended December 31, 2022. It contains standard sections found in an audit opinion, including the scope of the audit, the basis for the opinion, key audit matters, and the responsibilities of management and the auditor. This content directly corresponds to the definition of an Audit Report/Information (AR), which covers standalone audit reports and applied accounting principles, distinct from the full Annual Report (10-K) which contains the financial statements themselves plus management discussion and analysis, although this document reviews the annual financial statements. FY 2022
2023-05-08 Polish
Otrzymanie zaktualizowanego Sprawozdania niezależnego biegłego rewidenta z badania rocznego sprawozdania finansowego Spółki za 2022 rok - Content (PL)
Audit Report / Information Classification · 1% confidence The document text is in Polish and discusses an update to an 'Audit Report' ('Sprawozdanie niezależnego biegłego rewidenta z badania rocznego sprawozdania finansowego'). It explicitly mentions receiving an updated version of the auditor's report ('zaktualizowaną treść Sprawozdania') due to new evidence, and states that the updated report replaces the previously issued one. The core subject is the auditor's opinion on the annual financial statements. This aligns directly with the definition of an Audit Report / Information (AR), which covers standalone audit reports and applied accounting principles, even though it references the annual report context. Since this is the actual updated audit report content being communicated (or attached, as implied by 'przekazuje w formie załącznika'), it is classified as AR, not RPA. FY 2022
2023-05-08 Polish
Zawiadomienie z dnia 8 maja 2023 roku przekazane przez IPOPEMA Towarzystwo Funduszy Inwestycyjnych S.A.
Major Shareholding Notification Classification · 1% confidence The document is a formal notification from IPOPEMA Towarzystwo Funduszy Inwestycyjnych S.A. regarding a change in the shareholding percentage of the TOTAL Fundusz Inwestycyjny Zamknięty in Bioceltix Spółka Akcyjna. It explicitly cites Polish regulations concerning public offerings and public companies (art. 69 ust. 1 pkt 1 oraz art. 69a ust. 1 pkt 1 ustawy o ofercie publicznej...). The core content details the previous and current number of shares and the corresponding percentage of votes, indicating a crossing of a significant ownership threshold (from 3.39% to 9.30%). This directly matches the definition of a Major Shareholding Notification (MRQ). The document length is short, but its nature is a direct regulatory disclosure, not an announcement *about* a report, making MRQ more specific than RPA or RNS.
2023-05-08 Polish
Zawiadomienie o zmianie udziału w ogólnej liczbie głosów na Walnym Zgromadzeniu Emitenta - Content (PL)
Major Shareholding Notification Classification · 1% confidence The document text is very short (691 characters) and explicitly states that a notification received regarding an increase in voting rights (under Polish public offering law) is attached as an appendix ('Treść otrzymanego zawiadomienia stanowi załącznik do niniejszego raportu.'). This structure—a brief announcement referencing an attached or enclosed document—strongly suggests a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS), rather than the full content of the underlying report itself. Since the content specifically relates to a change in significant share ownership/voting rights, it is closely related to 'Major Shareholding Notification' (MRQ). However, the document itself is the *announcement* of receiving that notification, not the notification itself, and it is very brief. Given the options, and the nature of reporting regulatory events, RNS (Regulatory Filings) is the most appropriate fallback for a brief announcement of a regulatory event/document receipt, although MRQ is thematically close. Given the 'MENU VS MEAL' rule, where short announcements of attached documents lean towards RPA or RNS, and RNS is the general regulatory fallback, I will select RNS.
2023-05-08 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.